The authors say that 72% of their patients had asthma and 28% COPD. However the patients are unusual asthmatics in that they are relatively old (average age 65) and 62% patients smoked. Did the patients have lung function testing/ CT scanning etc to support the diagnoses? How sure are the authors of the diagnoses?
The small number of patients therefore categorised as having COPD in this study makes it difficult for the authors really to draw any conclusions about COPD and acute hyperglycaemia
The authors rely on physician diagnosis to identify patients with diabetes. As many patients with type 2 diabetes are undiagnosed (over half of those with diabetes and COPD in our own recent series) this may oversimplify the analysis. There are further complexities including treatment (we found that those on metformin had better long term survival than those not on metformin (Hitchings AW, Archer JRH, Srivastava SA, Baker EH. Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus. COPD 2014. Jun 10 [Epub ahead of print])) and duration of diabetes. The authors could address undiagnosed diabetes with their useful HbA1c data -perhaps including normal/elevated HbA1c as a binary variable in their analysis or using blood glucose/HbA1c data combined to categorise people as 1. No hyperglycaemia, no diabetes; 2. Hyperglycaemia, no diabetes; 3. No hyperglycaemia, diabetes and 4. Hyperglycaemia and diabetes. This could help them drill down into the impact of acute hyperglycaemia v diabetes I think that the authors overstate their conclusion that acute hyperglycaemia has no harmful effect. In our own study (ref 8 in their paper), acute hyperglycaemia in COPD patients was associated with increased risk of death or prolonged hospital stay, independent of a prior diagnosis of diabetes -worse short term prognosis from a COPD exacerbation. As they have few COPD patients in their study and patients had mild to moderate exacerbations (that wouldn't merit hospital admission in some other countries including ours) their study doesn't really explore poor early outcomes. It is interesting that in their study the late mortality relating from diabetes was due to cardiovascular disease. So perhaps taking the 2 studies together it would be more accurate to say that acute hyperglycaemia confers an early risk of doing badly from the COPD exacerbation whereas chronic hyperglycaemia confers a subsequent risk of death from cardiovascular disease.
The authors say that BNP data is included in the results -but I couldn't find it
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GENERAL COMMENTS
In this prospective observational study executed in 153 consecutive patients hospitalised for obstructive lung disease exacerbation in a single hospital in Finland the relation between plasma glucose levels and all-cause mortality was assessed during a main follow up of six years and two months. Druing follow up 57 (37%) patients died and a pre-exacerbation diagnosis of diabetes was associated with elevated mortality (adjusted HR 3.36; 95% CI 1.60-7.02). Hypeerglycaemia during exacerbation was not significantly related to mortality (adjusted HR not presented).I agree with the authors that hyperglycaemia was not statistically significantly related to all-cause mortality in these patients, but the study was far too small to conclude that "the clinical significance of hyperglycaemia during exacerbation and a systematic screening for hyperglycaemia in mild to moderate exacerbations is not advisable." Moreover, some associations seem to be strange and are not explained by the authors. For example, higher arterial blood oxygen saturation levels and higher diastolic blood pressure were beneficially related to mortality (Table 2) .
Major comments -In the abstract the authors mention they calculated survival at least 30 days after mild to moderate obstructive pulmonary disease exacerbation. This is somewhat misleading because only a single patient died within 30 days and on page 5 they mentioned they excluded this patient from the analyses.
-Also in the abstract should be mentioned that 72% had an asthma exacerbation and 28% a COPD exacerbation -In the abstract and results section the adjusted HR of mortality related to hyperglycaemia should be presented.
-The second part of the conclusion in the abstract is too far reaching and cannot be concluded from this study.
-How many patients refused participation? Selection? -Page 5. B-type natriuretic peptide, CRP , etc were measured but data not presented.
-How was the diagnosis of COPD and asthma established? Can we be sure these patients really had obstructive pulmonary disease and not unrecognized heart failure, sleep apnea, or pneumonia? -The authors should comment on 38% never smokers. How many had "asthma" and how many "COPD"? -The paragraph on statistical analysis is not well-written. The Cox regression analysis is not well described and seems to be executed wrongly. Why did the authors not impute missing values? -Page 9. Also results of adjusted HR for hyperglycaemia should be presented, preferably with exact mentioning of the confounders included in the model.
-The Discussion paragraph lacks a thorough discussion of the limitations of the study.
VERSION 1 -AUTHOR RESPONSE
REPLY TO THE REVIEWER 1.
We thank the reviewer for her valuable comments. Due to the comments of her and reviewer 2 the material has been totally reanalysed and the manuscript has been strongly revised. We hope that the changes satisfy the reviewer. Our replies have been written under each comment. The changes in the manuscript are written in red color.
Reviewer(s)' Comments to Author:
Reviewer: 1 Reviewer Name Professor Emma Baker Institution and Country St George's, University of London UK Please state any competing interests or state "None declared": I have published papers in this field
Strengths of the paper are: 7 blood glucose measurements on the first day of admission Prospective study with follow up Reporting of cause of death I would like the authors to address the following comments
The authors have considered asthma and COPD under the combined umbrella of obstructive lung disease. I think it is a mistake to lump them together as they are completely different diseases with different prognoses -asthma generally having a fairly good prognosis post exacerbation with COPD having ~50% 5 year mortality. This is confirmed by their own observation that asthma is protective and COPD predictive of late mortality (table 1) .
Reply: We acknowledge that pooling of asthma and COPD patients together may raise criticism. We would like to pool the groups also in the new manuscript. This was considered justified since all patients were subjected to the same, strong hyperglycaemia inducers, namely high doses of inhaled beta-2-adrenergic bronchodilators and oral glucocorticoids, and thus form a distinct clinical entity. Furthermore, it is well known that there is a large group of patients with features from both conditions. Even more importantly, it is often impossible to differentiate them in an emergency setting. In this respect our study setting mimics the real-life situation. Unfortunately, we do not have comprehensive spirometric data to reliably differentiate the two conditions. This shortcoming is now mentioned in the revised manuscript. The diagnosis was based merely on the attending physician's opinion. However, the presence of probable COPD was included in all multivariate models which should statistically overcome the problem. We have tried to describe these limitations of the study better in the revised manuscript, see page 14, third paragraph. Finally, we would like to highlight that pooling of asthma and COPD patients has taken place also in previous studies about long-term prognosis after obstructive lung disease exacerbations ( The authors say that 72% of their patients had asthma and 28% COPD. However the patients are unusual asthmatics in that they are relatively old (average age 65) and 62% patients smoked. Did the patients have lung function testing/ CT scanning etc to support the diagnoses? How sure are the authors of the diagnoses?
Reply: The authors are not at all sure about their diagnoses and similar uncertainty is probably familiar to most clinicians managing acute exacerbations of obstructive lung diseases . That is why we have pooled the groups in the analysis. See our reply to the previous comment. The probable asthmatics were mean 62.6 (59.6 -65.6) years old and 49 % were ever smokers. The probable COPD patients were 70.7 (68.3 -73.1) years old and 95 % were ever smokers. All this underline our view that the two groups overlap and therefore, they could be pooled together. As written in the previous reply we neither have spirometric data nor CT data to reliably differentiate the groups. This shortcoming is expressed in the manuscript (page 5, second paragraph, and page 14, third paragraph.
The small number of patients therefore categorised as having COPD in this study makes it difficult for the authors really to draw any conclusions about COPD and acute hyperglycaemia Reply: As mentioned before, in a real-life clinical setting the physician is often uncertain about the exact diagnosis (acute asthma or COPD). He/she only meets a group of patients treated with large doses of of inhaled beta-2-adrenergic bronchodilators and oral glucocorticoids and wonders how to react to hyperglycemia among them.
The authors rely on physician diagnosis to identify patients with diabetes. As many patients with type 2 diabetes are undiagnosed (over half of those with diabetes and COPD in our own recent series) this may oversimplify the analysis. There are further complexities including treatment (we found that those on metformin had better long term survival than those not on metformin (Hitchings AW, Archer JRH, Srivastava SA, Baker EH. Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus. COPD 2014. Jun 10 [Epub ahead of print])) and duration of diabetes. The authors could address undiagnosed diabetes with their useful HbA1c data -perhaps including normal/elevated HbA1c as a binary variable in their analysis or using blood glucose/HbA1c data combined to categorise people as 1. No hyperglycaemia, no diabetes; 2. Hyperglycaemia, no diabetes; 3. No hyperglycaemia, diabetes and 4. Hyperglycaemia and diabetes. This could help them drill down into the impact of acute hyperglycaemia v diabetes Reply: We thank the reviewer for these very valuable and constructive comments. It is true that a great proportion of diabetics are underdiagnosed. In the new manuscript we divide the patients to three groups: Those with a doctor's diagnosis of diabetes, those with a screening diagnosis of diabetes (no doctor's diagnosis but HbA1c ≥ 6.5 %) and those without any form of diabetes.
Thanks to the reviewer's suggestion we have now analysed the association of metformin with the late mortality. We have complete data about all medication that the patients used during the exacerbation. Naturally, metformin medication was withheld during the hospitalization but continued after it (page 6, first paragraph). We included both the doctor's diagnosis and metformin medication in the same multivariate Cox model (page 9, second paragraph). We could not find evidence about survival benefit by metformin. Actually, metformin was associated with an increased mortality. In the discussion (page 14, second paragraph) we stress that the association between metformin and the late mortality was not the main objective of the present study and that the patient numbers are far too small to draw any conclusions about the safety of metformin in asthmatic patients.
I think that the authors overstate their conclusion that acute hyperglycaemia has no harmful effect. In our own study (ref 8 in their paper), acute hyperglycaemia in COPD patients was associated with increased risk of death or prolonged hospital stay, independent of a prior diagnosis of diabetesworse short term prognosis from a COPD exacerbation. As they have few COPD patients in their study and patients had mild to moderate exacerbations (that wouldn't merit hospital admission in some other countries including ours) their study doesn't really explore poor early outcomes. It is interesting that in their study the late mortality relating from diabetes was due to cardiovascular disease. So perhaps taking the 2 studies together it would be more accurate to say that acute hyperglycaemia confers an early risk of doing badly from the COPD exacerbation whereas chronic hyperglycaemia confers a subsequent risk of death from cardiovascular disease. In this prospective observational study executed in 153 consecutive patients hospitalised for obstructive lung disease exacerbation in a single hospital in Finland the relation between plasma glucose levels and all-cause mortality was assessed during a main follow up of six years and two months.
Druing follow up 57 (37%) patients died and a pre-exacerbation diagnosis of diabetes was associated with elevated mortality (adjusted HR 3.36; 95% CI 1.60-7.02). Hypeerglycaemia during exacerbation was not significantly related to mortality (adjusted HR not presented).I agree with the authors that hyperglycaemia was not statistically significantly related to all-cause mortality in these patients, but the study was far too small to conclude that "the clinical significance of hyperglycaemia during exacerbation and a systematic screening for hyperglycaemia in mild to moderate exacerbations is not advisable." Moreover, some associations seem to be strange and are not explained by the authors. For example, higher arterial blood oxygen saturation levels and higher diastolic blood pressure were beneficially related to mortality (Table 2) .
Reply: We agree that we made too straightforward conclusions. We have made substantial changes to the manuscript to address the reviewer's concern. About the strange associations, in the revised version of the manuscript we have produced receiver operator curves (ROC) for the continuous variables to define the best cut-off values to predict death during the follow-up. By this way it may be easier to express the associations between the baseline characteristics and late mortality (table 2) . It can be seen that low oxygen saturation and low diastolic blood pressure were associated with increased mortality.
Reply: In many previous studies early (within 30 days) and late mortality (from 30 days on) has not been clearly separated. The prognostic factors for early and late mortality differ considerably. We tried to express clearly that the present study investigated the factors affecting the late mortality.
-Also in the abstract should be mentioned that 72% had an asthma exacerbation and 28% a COPD exacerbation
Reply: This is now mentioned in the abstract.
-In the abstract and results section the adjusted HR of mortality related to hyperglycaemia should be presented.
Reply : These values have now been added, see abstract and table 3. -The second part of the conclusion in the abstract is too far reaching and cannot be concluded from this study.
Reply: True. It has been rewritten.
-How many patients refused participation? Selection?
Reply: This information has been added to the manuscript, page 5, first paragraph.
-Page 5. B-type natriuretic peptide, CRP , etc were measured but data not presented.
Reply: In the revised manuscript this information is presented, see page 9, first paragraph.
-How was the diagnosis of COPD and asthma established? Can we be sure these patients really had obstructive pulmonary disease and not unrecognized heart failure, sleep apnea, or pneumonia?
Reply: The diagnosis was based on the attending physician's opinion at discharge. So, patients who had been admitted due to a suspicion of asthma/COPD exacerbation but who were found to suffer from some other disease during the hospitalisation, were not included.
-The authors should comment on 38% never smokers. How many had "asthma" and how many "COPD"?
Reply: The information about the smoking status has been added to the text, see page 5, first paragraph.
-The paragraph on statistical analysis is not well-written. The Cox regression analysis is not well described and seems to be executed wrongly. Why did the authors not impute missing values?
Reply: The chapter "statistical analysis" is strongly revised. However, we are unwilling to impute missing values which would rely on estimations about the missing values based on other patients' data.
-Page 9. Also results of adjusted HR for hyperglycaemia should be presented, preferably with exact mentioning of the confounders included in the model.
Reply: This information can now be found in table 3.
Reply: We have tried to describe the limitations of the study better in the revised manuscript, see page 14, third paragraph. 
GENERAL COMMENTS
The authors managed to address the majority of my concerns.
There remain some items that may improve the manuscript.
-Given the change in conclusion, I would suggest to change the title in something like: "A history of diabetes and not hyperglaecemia during exacerbation of obstructive lung disease has impact on longterm mortality. A prospective, observational cohort study" -The conclusion in the abstract may also be changed given the results. The authors now provide the HRs of fasting glucose levels and postprandial levels in patients with OPD and known with diabetes and unknown with diabetes. Because the HRs become close to 1 when "history of diabetes" is included in the model, and was already close to 1 in those unknown with diabetes, one can conclude that knowing whether the patient has diabetes is sufficient. Laboratory testing of glucose in the acute setting does not add to the prediction of long-term all cause mortality.
-I would prefer the authors mention in the abstract that the study was performed in a single hospital in Finland and that the mean follow up was six years and two months in those who survived the first 30 days.
-The discussion paragraph improved a lot and now includes an adequate limitation section. The conclusion of the discussion paragraph may be changed in line with my suggestions regarding the conclusion in the abstract. Moreover, the clinical implications of the results may be better addressed. One may conclude that measuring fasting glucose during exacerbation has no impact on long-term all cause mortality. Even detecting new cases of diabetes did not add.
-The methods section is still very short and did not changed substantially to the first submission. I would like the authors to provide some more information on how exactly they applied the Cox regression analysis.
